Progress in the treatment of psoriasis is undeniable. However, not everything Griffiths and colleagues discuss has come to ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Researchers at the University of Copenhagen have developed an electrospun nanofibre patch for the easier and more effective ...

Psoriasis severity and systemic inflammation linked to cardiovascular disease: insights for better patient care.

Discover how immune checkpoint inhibitors, a revolutionary cancer therapy, increase psoriasis risk. Essential insights for ...

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

PASI was associated with GlycA levels and cardiovascular disease in both studies. GlycA levels were independently associated ...

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...